Kyverna Therapeutics, Inc. Common Stock
$7.13
$0.09 (+1.28%)
$7.00Day Range$7.19
Key Statistics
Market Cap
$435.38M
Shares Outstanding
61.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 8, 2024
Round Lot
100
Locale
US
Trading Data
Day Open
$7.02
Day High
$7.19
Day Low
$7.00
Volume
961.3K
VWAP
$7.11
Prev Close
$7.04
Transactions
--
Acc. Volume
--
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836149 employees5980 HORTON STREET, EMERYVILLE, CA(510) 925-2492IPO Feb 8, 2024US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001994702
- Composite FIGI
- BBG00RCYMHR1
- Share Class FIGI
- BBG00RCYMHS0
- Ticker Root
- KYTX
- SIC Code
- 2836
About Kyverna Therapeutics, Inc. Common Stock (KYTX) Stock
Kyverna Therapeutics, Inc. Common Stock (KYTX) closed the 2026-09-18 session at $7.13, up 1.28% versus the previous close (+0.09). The stock opened at $7.02 and traded between $7.00 and $7.19 during that session. Session trading volume was 961K shares. The volume-weighted average price (VWAP) is $7.11.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Kyverna Therapeutics, Inc. Common Stock has a market capitalization of $435.4 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. KYTX is listed on the XNAS exchange. The company employs approximately 149 people. Kyverna Therapeutics, Inc. Common Stock is headquartered in EMERYVILLE, CA. The recorded listing date is 2024-02-08.
On this page you can find market KYTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.